Aurinia Pharmaceuticals Inc.
NASDAQ:AUPH
7.69 (USD) • At close January 15, 2025
Overzicht | Financiële gegevens
Bedrijfsnaam | Aurinia Pharmaceuticals Inc. |
Symbool | AUPH |
Munteenheid | USD |
Prijs | 7.69 |
Beurswaarde | 1,101,046,510 |
Dividendpercentage | 0% |
52-weken bereik | 4.71 - 10.67 |
Industrie | Biotechnology |
Sector | Healthcare |
CEO | Mr. Peter S. Greenleaf M.B.A. |
Website | https://www.auriniapharma.com |
An error occurred while fetching data.
Over Aurinia Pharmaceuticals Inc.
Aurinia Pharmaceuticals Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies to treat various diseases with unmet medical need in the United States and internationally. The company offers LUPKYNIS for the treatment of adult patients with active lupus nephritis. It has a collaboration and license agreement with Otsuka
Vergelijkbare Aandelen
Financiële Gegevens
Cijfers zijn in miljoenen (USD)
Cijfers zijn in miljoenen (USD)